Indivior supplements proxy disclosures for Supernus merger ahead of October 15 vote
Indivior filed added disclosures on October 6, 2026, revising financial advisor figures in the joint proxy statement/prospectus after Supernus stockholder demand letters and lawsuits alleged disclosure gaps.
Indivior Pharmaceuticals, Inc. filed an 8-K on October 6, 2026 supplementing the definitive joint proxy statement/prospectus tied to its pending merger with Supernus Pharmaceuticals, Inc. The companies entered an Agreement and Plan of Merger on August 1, 2026, under which a merger subsidiary will merge into Supernus, leaving Supernus as a wholly owned subsidiary of Indivior, with Indivior then renamed Supernus, Inc.1
Indivior had filed a Form S-4 registration statement on August 28, 2026, which was later amended and declared effective by the SEC on September 11, 2026; the definitive joint proxy statement/prospectus included in that registration statement was first mailed to stockholders of both companies on that date.1 Each company plans to hold a special stockholder meeting on October 15, 2026 related to the merger.1
The supplement followed demand letters and two lawsuits filed in the Supreme Court of the State of New York by purported Supernus stockholders, alleging disclosure deficiencies or incomplete information in the proxy statement.1 Supernus said it viewed the claims as without merit and denied wrongdoing, but agreed to add disclosures to avoid litigation costs, delay risk, and to moot the claims, without admitting any legal requirement to do so.1
The added disclosures revise several financial advisor Cantor Fitzgerald metrics in the proxy. For example, Cantor's discounted cash flow analysis for Supernus, after dividing by a revised range of about 61.0 million to 61.7 million fully diluted shares, produced an implied per-share equity value range of $50.55 to $59.50.1 For Indivior, a revised share count of roughly 124.0 million to 139.3 million fully diluted shares produced a dividend-adjusted implied per-share value range of $24.20 to $43.90.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.